METASTASES TO ABDOMINAL CAVITY side effect
What is METASTASES TO ABDOMINAL CAVITY ?METASTASES TO ABDOMINAL CAVITY : Actonel Side Effects Report #5491338-8
Physician from CANADA reported ACTONEL problem on Oct 05, 2007. Female patient, 81 years of age, weighting 95.02 lb, was diagnosed with osteoporosis and was treated with ACTONEL. After drug was administered, patient experienced the following problems/side effects: hypertension, metastases to abdominal cavity, ovarian cancer metastatic, . ACTONEL dosage: 35 MG, 1/WEEK, ORAL. During the same period patient was treated with SYNTHROID, MIACALCIN, PANTOPRAZOLE. Patient was hospitalized and became disabled. Patient recovered.
METASTASES TO ABDOMINAL CAVITY : Infliximab Side Effects Report #5591191-8
INFLIXIMAB problem was reported by a Physician from UNITED STATES on Jan 09, 2008. Male patient, weighting 161.0 lb, was treated with INFLIXIMAB. After drug was administered, patient experienced the following problems/side effects: abdominal pain, colon cancer, metastases to abdominal cavity, signet-ring cell carcinoma, . INFLIXIMAB dosage: unknown. Patient was hospitalized. Patient died on 10/08/2007.
METASTASES TO ABDOMINAL CAVITY : Prograf Side Effects Report #5419995-2
Physician from JAPAN reported PROGRAF problem on Aug 02, 2007. Female patient, 41 years of age, was diagnosed with myasthenia gravis and was treated with PROGRAF. After drug was administered, patient experienced the following problems/side effects: graft versus host disease, malignant neoplasm progression, metastases to abdominal cavity, metastasis, respiratory failure, thymoma malignant recurrent, . PROGRAF dosage: 3 MG, UID/QD, ORAL. During the same period patient was treated with MYTELASE, PREDNISOLONE, ATROPINE SULPHATE, GASTERLET, SELBEX, BIOFERMIN. Patient died on 12/29/2005.
METASTASES TO ABDOMINAL CAVITY : Cenestin Side Effects Report #5379575-4
CENESTIN problem was reported by a Consumer or non-health professional from JAPAN on May 21, 2007. Female patient, 40 years of age, was diagnosed with oestradiol decreased and was treated with CENESTIN. After drug was administered, patient experienced the following problems/side effects: endometrial cancer metastatic, lipid metabolism disorder, metastases to abdominal cavity, metastases to liver, metastases to lymph nodes, . CENESTIN dosage: 0.625 MG. During the same period patient was treated with MEDROXYPROGESTERONE. Patient died.
METASTASES TO ABDOMINAL CAVITY : Cenestin Side Effects Report #5379575-4
Consumer or non-health professional from JAPAN reported CENESTIN problem on May 21, 2007. Female patient, 40 years of age, was diagnosed with oestradiol decreased and was treated with CENESTIN. After drug was administered, patient experienced the following problems/side effects: endometrial cancer metastatic, lipid metabolism disorder, metastases to abdominal cavity, metastases to liver, metastases to lymph nodes, . CENESTIN dosage: 0.625 MG. During the same period patient was treated with MEDROXYPROGESTERONE. Patient died.